Pfizer nabs Roslin Cells in cell therapy manufacturing deal

By Zachary Brennan

- Last updated on GMT

Pfizer nabs Roslin Cells in cell therapy manufacturing deal

Related tags Retina

Roslin Cells has signed a contract with Neusentis, a research unit of Pfizer based in Cambridge, UK, to support the manufacture of retinal pigment epithelium (RPE) cells to be used in a cell therapy clinical trial.  

This trial will evaluate the therapy for the treatment of patients suffering from age related macular degeneration (AMD), the major cause of loss of vision in people aged 65 and older, as part of an ongoing collaboration with The London Project at the Institute of Ophthalmology, UCL.

Manufacturing will take place in the company’s GMP Cellular Therapy Manufacturing Facility in Edinburgh, which was licensed by the Medicines Healthcare Products Regulatory Agency in May 2013 for the manufacture of human cell therapy products for clinical trials. 

Speaking on the deal, Janet Downie, COO of Roslin Cells, told, “We are currently using a range of tissue culture flasks within the facility.  We are currently evaluating bioreactors but have not introduced [any] yet​.”

The 5,000-square-foot facility still has capacity to take on new projects later in the year, Downie noted.  We are also manufacturing for ReNeuron with a plan to supply the phase 2 stroke trial.

Aidan Courtney, CEO of Roslin Cells, added, “This contract builds on our success to secure other leading cell therapy programmes and demonstrates our position in regenerative medicine in Europe.  It represents the culmination of a four year programme to design, build and commission a premier facility for cell therapy development here in Edinburgh.​”

The manufacturing facility runs in partnership with the Scottish National Blood Transfusion Service. In addition to manufacturing established cellular products, Roslin supports commercial and academic clients, including early phase GMP manufacturing of cellular therapies for clinical trials. 

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more